ReviewBiomolecules2022
Recent Progress in Second Near-Infrared (NIR-II) Fluorescence Imaging in Cancer.
Review in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- NIR-II squeezed light-field microscopy enables high-speed volumetric imaging of deep-tissue dynamicsbioRxiv : the preprint server for biology · 2026Article
- Preliminary Application of TROP2-Targeted Peptide Screening for Real-Time Intraoperative Navigation in Pancreatic Cancer.Chemical & biomedical imaging · 2026Article
- Precursor-dependent optical and structural properties of eleven NIR-emissive graphene quantum dots for bioimaging applications.2d materials · 2026Article
- Article
- Luminescence Fingerprint of Intracellular NIR-II Gold Nanocluster Transformation: Implications for Sensing and Imaging.ACS nano · 2025Article
- BLEscope: A Bluetooth Low Energy (BLE) Microscope for Wireless Multicontrast Functional Imaging.IEEE transactions on bio-medical engineering · 2025Article
- NIR-II Imaging Guided Accurate Identification of Paraspinal Muscle Degeneration Through Targeting the Lysosomal Membrane Protein Sidt2.International journal of nanomedicine · 2025Article
- Non-invasive early-stage cancer detection: current methods and future perspectives.Clinical and experimental medicine · 2024Review
- Review
- 2Molecular imaging and biology · 2024Article
- ImmunoPET provides a novel way to visualize the CD103EJNMMI research · 2024Review
- Optical imaging for early detection of cervical cancer: state of the art and perspectives.Journal of biomedical optics · 2023Review
- Cancer Therapeutic siRNA Delivery and Imaging by Nitrogen- and Neodymium-Doped Graphene Quantum Dots.ACS biomaterials science & engineering · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer continues to be one of the leading causes of death worldwide, and its incidence is on the rise. Although cancer diagnosis and therapy have advanced significantly in recent decades, it is still a challenge to achieve the accurate identification and localization of cancer and to complete tumor elimination with a maximum preservation of normal tissue. Recently, second near-infrared region (NIR-II, 1000-1700 nm) fluorescence has shown great application potential in cancer theranostics due to its inherent advantages, such as great penetration capacity, minimal tissue absorption and scattering, and low autofluorescence. With the development of fluorescence imaging systems and fluorescent probes, tumor detection, margin definition, and individualized therapy can be achieved quickly, enabling an increasingly accurate diagnosis and treatment of cancer. Herein, this review introduces the role of NIR-II fluorescence imaging in cancer diagnosis and summarizes the representative applications of NIR-II image-guided treatment in cancer therapy. Ultimately, we discuss the present challenges and future perspectives on fluorescence imaging in the field of cancer theranostics and put forward our opinions on how to improve the accuracy and efficiency of cancer diagnosis and therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.